Tissue-type plasminogen activator, urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and u-PA–PAI-1 complexes in patients and controls measured by enzyme-linked immunosorbent assays
| Protein . | Sample . | n . | ng/mL plasma or ng/109 platelets . | P . | ||
|---|---|---|---|---|---|---|
| Mean ± SD . | Range . | |||||
| t-PA | Plasma | Q | 8 | 6.3 ± 2.7 | 3.7-11.2 | .87 |
| C | 8 | 6.1 ± 2.0 | 4.3-9.8 | |||
| t-PA | Platelets | Q | 5 | All values < 2 | All values < 2 | — |
| C | 20 | All values < 2 | All values < 2 | |||
| u-PA, AD | Plasma | Q | 12 | 2.3 ± 1.2 | 0.8-4.6 | < .0009 |
| C | 20 | 0.7 ± 0.3 | < 0.5-1.9‡ | |||
| u-PA, OS | Plasma | Q | 12 | 7.0 ± 6.7 | 1.9-22.6 | < .02 |
| C | 20 | 1.2 ± 0.6 | 0.6-2.7 | |||
| u-PA, AD | Platelets | Q | 5 | 123 ± 16 | 106-143 | < .00008 |
| C | 20 | 0.4 ± 0.2 | < 0.25-0.75† | |||
| u-PA, AD | Stored platelets | Q | 9 | 76 ± 28 | 45-122 | < .00006 |
| C* | 5 | All values < 5 | All values < 5 | |||
| u-PA, OS | Platelets | Q | 5 | 505 ± 70 | 409-603 | < .00009 |
| C | 20 | 0.8 ± 0.2 | 0.4-1.3 | |||
| PAI-1 | Platelets | Q | 5 | 954 ± 162 | 816-1161 | < .0008 |
| C | 20 | 407 ± 96 | 286-660 | |||
| u-PA–PAI-1 complexes | Platelets | Q | 5 | 95 ± 14 | 82-115 | < .0002 |
| C | 20 | 0.9 ± 0.2 | 0.6-1.3 | |||
| Protein . | Sample . | n . | ng/mL plasma or ng/109 platelets . | P . | ||
|---|---|---|---|---|---|---|
| Mean ± SD . | Range . | |||||
| t-PA | Plasma | Q | 8 | 6.3 ± 2.7 | 3.7-11.2 | .87 |
| C | 8 | 6.1 ± 2.0 | 4.3-9.8 | |||
| t-PA | Platelets | Q | 5 | All values < 2 | All values < 2 | — |
| C | 20 | All values < 2 | All values < 2 | |||
| u-PA, AD | Plasma | Q | 12 | 2.3 ± 1.2 | 0.8-4.6 | < .0009 |
| C | 20 | 0.7 ± 0.3 | < 0.5-1.9‡ | |||
| u-PA, OS | Plasma | Q | 12 | 7.0 ± 6.7 | 1.9-22.6 | < .02 |
| C | 20 | 1.2 ± 0.6 | 0.6-2.7 | |||
| u-PA, AD | Platelets | Q | 5 | 123 ± 16 | 106-143 | < .00008 |
| C | 20 | 0.4 ± 0.2 | < 0.25-0.75† | |||
| u-PA, AD | Stored platelets | Q | 9 | 76 ± 28 | 45-122 | < .00006 |
| C* | 5 | All values < 5 | All values < 5 | |||
| u-PA, OS | Platelets | Q | 5 | 505 ± 70 | 409-603 | < .00009 |
| C | 20 | 0.8 ± 0.2 | 0.4-1.3 | |||
| PAI-1 | Platelets | Q | 5 | 954 ± 162 | 816-1161 | < .0008 |
| C | 20 | 407 ± 96 | 286-660 | |||
| u-PA–PAI-1 complexes | Platelets | Q | 5 | 95 ± 14 | 82-115 | < .0002 |
| C | 20 | 0.9 ± 0.2 | 0.6-1.3 | |||
Data for patients and controls were compared using two-tailed, Student t tests. Results for AD and OD u-PA ELISA are shown separately.
t-PA indicates tissue-type plasminogen activator; u-PA, urokinase-type plasminogen activator; PAI-1, plasminogen activator inhibitor 1; ELISA, enzyme-linked immunosorbent assays; AD, American Diagnostica; OS, Oncogene Science; Q, patients; C, controls.
Control subjects who were unaffected relatives.
Tested at 1:2.5 dilutions.
Tested at 1:5 dilutions.
Two of 20 control platelet lysates and 5 of 20 control plasmas contained less u-PA than the lowest standard of the AD ELISA. Stored platelet lysates were tested at 1:50 and larger dilutions in the AD u-PA ELISA only because sample volumes were limited.